scholarly journals Fluorescence-guided craniotomy of glioblastoma using panitumumab-IRDye800

2022 ◽  
Vol 6 (1) ◽  
pp. V9
Keyword(s):  
Near Infrared ◽  
Ex Vivo ◽  
Growth Factor Receptor ◽  
Tumor Removal ◽  
En Bloc ◽  
Postoperative Mri ◽  
Visual Contrast ◽  
Resected Tumor ◽  
Epidermal Growth ◽  
Egfr Antibody

A contrast-enhancing lesion in the left temporal lobe of a 72-year-old woman was biopsied and diagnosed as glioblastoma. Near-infrared (NIR)–labeled epidermal growth factor receptor (EGFR) antibody, panitumumab-IRDye800, was infused 52 hours before craniotomy without pretreatment. Tumor fluorescence was detected through intact dura, and the visual contrast between disease and peritumoral healthy brain was enhanced after tumor exposure. Residual cancerous tissue was identified with strong fluorescence in resection cavity after en bloc tumor removal. Minimal fluorescence remained in the final wound bed, likely from nonenhancing tumor. Fluorescence was heterogeneously distributed at the infiltrative margin in resected tumor pieces imaged ex vivo. Postoperative MRI confirmed gross-total resection. The video can be found here: https://stream.cadmore.media/r10.3171/2021.10.FOCVID21201

scholarly journals Antibody-Dye Conjugate Detects Epidermal Growth Factor Receptor Expression in High-Graded Gliomas: A Feasibility Study for Fluorescence-Guided Resection

2020 ◽  
Author(s):  
Quan Zhou ◽  
Johana Vega Leonel ◽  
Michelle Santoso ◽  
Christy Wilson ◽  
Nynke van den Berg ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Near Infrared ◽  
Ex Vivo ◽  
Growth Factor Receptor ◽  
Egfr Expression ◽  
Epidermal Growth ◽  
Specific Uptake

Abstract Background: The prognosis for high-grade glioma (HGG) remains dismal and extent of resection correlates with overall survival and progression free disease. Epidermal growth factor receptor (EGFR) is a biomarker heterogeneously expressed in HGG. We assessed the feasibility of detecting HGG using near-infrared fluorescent antibody targeting EGFR. Methods: Mice bearing orthotopic HGG xenografts with modest EGFR expression were imaged in vivo after systemic panitumumab-IRDye800 injection to assess its tumor-specific uptake macroscopically over 14 days, and microscopically ex vivo. EGFR immunohistochemical staining of 59 tumor specimens from 35 HGG patients during was scored by pathologists and expression levels were compared to that of mouse xenografts. Results: Intratumoral distribution of pan800 correlated with near-infrared fluorescence and EGFR expression. Fluorescence distinguished tumor cells with 90% specificity and 82.5% sensitivity. Target-to-background ratios peaked at 14 hours post panitumumab-IRDye800 infusion, reaching 19.5 in vivo and 7.6 ex vivo, respectively. Equivalent or higher EGFR protein expression compared to the mouse xenografts was present in 77.1% HGG patients. Age, combined with IDH-wildtype cerebral tumor, was predictive of greater EGFR protein expression in human tumors. Conclusion: Tumor specific uptake of pan800 provided remarkable contrast and a flexible imaging window for fluorescence-guided identification of HGGs despite modest EGFR expression.

scholarly journals Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody

Oncotarget ◽  
2018 ◽  
Vol 9 (27) ◽  
pp. 19026-19038 ◽  
Author(s):  
Tadanobu Nagaya ◽  
Shuhei Okuyama ◽  
Fusa Ogata ◽  
Yasuhiro Maruoka ◽  
Deborah W. Knapp ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Near Infrared ◽  
Growth Factor Receptor ◽  
Epidermal Growth ◽  
Egfr Antibody

scholarly journals Molecular imaging of a fluorescent antibody against epidermal growth factor receptor detects high-grade glioma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Quan Zhou ◽  
Johana C. M. Vega Leonel ◽  
Michelle Rai Santoso ◽  
Christy Wilson ◽  
Nynke S. van den Berg ◽  
...  
Keyword(s):  
Near Infrared ◽  
Ex Vivo ◽  
Fluorescent Antibody ◽  
Growth Factor Receptor ◽  
High Grade Glioma ◽  
High Grade ◽  
Egfr Expression ◽  
Epidermal Growth ◽  
Specific Uptake

AbstractThe prognosis for high-grade glioma (HGG) remains dismal and the extent of resection correlates with overall survival and progression free disease. Epidermal growth factor receptor (EGFR) is a biomarker heterogeneously expressed in HGG. We assessed the feasibility of detecting HGG using near-infrared fluorescent antibody targeting EGFR. Mice bearing orthotopic HGG xenografts with modest EGFR expression were imaged in vivo after systemic panitumumab-IRDye800 injection to assess its tumor-specific uptake macroscopically over 14 days, and microscopically ex vivo. EGFR immunohistochemical staining of 59 tumor specimens from 35 HGG patients was scored by pathologists and expression levels were compared to that of mouse xenografts. Intratumoral distribution of panitumumab-IRDye800 correlated with near-infrared fluorescence and EGFR expression. Fluorescence distinguished tumor cells with 90% specificity and 82.5% sensitivity. Target-to-background ratios peaked at 14 h post panitumumab-IRDye800 infusion, reaching 19.5 in vivo and 7.6 ex vivo, respectively. Equivalent or higher EGFR protein expression compared to the mouse xenografts was present in 77.1% HGG patients. Age, combined with IDH-wildtype cerebral tumor, was predictive of greater EGFR protein expression in human tumors. Tumor specific uptake of panitumumab-IRDye800 provided remarkable contrast and a flexible imaging window for fluorescence-guided identification of HGGs despite modest EGFR expression.

scholarly journals Panitumumab-induced pulmonary toxicity

2019 ◽  
Vol 26 (5) ◽  
Author(s):  
R. Arora ◽  
M. Kisiel ◽  
C. MacColl
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Pulmonary Toxicity ◽  
White Woman ◽  
Antibody Therapy ◽  
Growth Factor Receptor ◽  
Colorectal Cancers ◽  
Japanese Men ◽  
Life Threatening ◽  
Epidermal Growth ◽  
Egfr Antibody

Mutations in EGFR have been implicated in the pathogenesis of various types of cancer, and therefore antibody therapy directed against the epidermal growth factor receptor (egfr) is increasingly being used in the management of various cancers. Currently, anti-egfr antibodies are used mainly in the management of cancers of the head and neck and metastatic colorectal cancers. Because of this increasing use, we would like to inform the oncology community in North America of a rare, but life-threatening, toxicity associated with anti-egfr antibody therapy. Although cases in white and Japanese men have been documented, we present the first known North American report of panitumumab-induced pulmonary toxicity in a white woman.

A Potential Molecular Approach to Ex Vivo Hematopoietic Expansion With Recombinant Epidermal Growth Factor Receptor-Expressing Adenovirus Vector

Blood ◽  
1998 ◽  
Vol 91 (12) ◽  
pp. 4509-4515 ◽  
Author(s):  
Tokiharu Takahashi ◽  
Kaoru Yamada ◽  
Tomoyuki Tanaka ◽  
Keiki Kumano ◽  
Mineo Kurokawa ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Ex Vivo ◽  
Growth Factor Receptor ◽  
Adenovirus Vector ◽  
Ex Vivo Expansion ◽  
Molecular Approach ◽  
Hematopoietic Progenitors ◽  
Epidermal Growth

Abstract Ex vivo expansion of hematopoietic stem cell (HSC) is an attractive technology for its potency of a variety of clinical applications. Such a technology has been achieved to some extent with combinations of various cytokines or continuous perfusion cultures. However, much more improvement is required especially for expansion of primitive hematopoietic progenitors. We propose here a novel molecular approach that might have the potential to compensate the current expansion. We designed an adenovirus vector to transiently express human epidermal growth factor receptor (EGFR), which is known to transduce only a mitogenic, but not a differentiation signal to mouse bone marrow cells on human purified CD34+ peripheral blood (PB) cells, and tried to expand these cells with EGF ex vivo. Because we found that exposure of CD34+ PB cells to cytokines induced surface expression of adenovirus-internalization receptor and rendered these cells permissive to adenovirus infection, we infected these cells with the adenovirus vector carrying EGFR gene in the presence of cytokines. Two-color flow cytometric analysis demonstrated that 60.3% ± 22.4% of CD34+ cells expressed the adenovirus-mediated EGFR. Moreover, long-term culture-initiating cell assay showed that adenovirus vector could transduce more primitive progenitors. Subsequently, we tried to expand these cells in suspension culture with EGF for 5 days. Methylcellulose clonal assay showed that EGF induced 5.0- ± 2.4-fold proliferation of the colony-forming unit pool during 5 days of expansion. The simple procedure of efficient adenovirus gene delivery to immature hematopoietic cells proved promising, and this technique was potentially applicable for a novel strategy aiming at ex vivo expansion of hematopoietic progenitors.

Sign in / Sign up

Export Citation Format

Share Document